Brian L. Clevinger is a founder and managing director of Prolog. Brian has actively participated in all phases of commercial technology development for nearly two decades. Before Prolog, he was the CEO of Megan Health, a vaccine developer. He held this position from Megan's inception until its acquisition by AVANT Immunotherapeutics (NASDAQ: AVAN). Previously, he was the president of A/W Company, a technology transfer partnership of the private equity firm Alafi Capital and Washington University in St. Louis. Working with Washington University researchers, he evaluated numerous technologies, selected the most commercially promising ones for funding, and served on the board of each resulting enterprise. Before joining A/W Company, he held a tenured position and headed a research laboratory at Washington University. Brian holds a doctoral degree in immunology from Indiana University and has completed his postdoctoral fellowship at Washington University.

Prolog Portfolio Companies:

• Chlorogen, Director
• Metaphore, Observer
• ZyStor Therapeutics, Director